维普中文期刊产品整合服务
124篇 您的检索式:作者名="Lubel"
    题名 作者 年代 出处 被引量
1Natural history of chronic hepatitis B:Phases in a complex relationship显示文摘Chronic hepatitis B(CHB)is a condition of globalprevalence and its sequelae include cirrhosis and hepatocellular carcinoma.The natural history of CHB isa complex interplay of virological,environmental andhost factors.The dynamic relationship between thevirus and host evolves over the duration of the infection and different phases of the disease have been observed and described.These have been conceptualizedin terms of the state of balance between the host immune system and the hepatitis B virus and have beengiven the labels immune tolerant,immune clearance,immune control and immune escape although othernomenclature is also used.Host factors,such as age atinfection,determine progression to chronicity.Virological factors including hepatitis B viral load,mutationsand genotype also have an impact on the adverseoutcomes of the infection,as do hepatotoxic cofactorssuch as alcohol.Our understanding of the natural history of CHB has evolved significantly over the past fewdecades and characterizing the phase of disease ofCHB remains an integral part of managing this virus in the clinic.Catherine MN Croagh John S Lubel 2014World Journal of Gastroenterology2014,20,30:32
2Review article: vitamin D and inflammatory bowel disease – established concepts and future directions显示文摘M. Garg J. S. Lubel M. P. Sparrow S. G. Holt P. R. Gibson 2012Aliment Pharmacol Ther2012,,4:2
3Rho signaling pathway targeted to promote spi- nal cord repair显示文摘Dergham P Ellezam B Essagian C Avedissian H Lubell WD McKerracher L 2002Neurosei2002,22,:1
4Angiotensin-(1- 7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotie activity in the bile-duct-ligated rat显示文摘Lubel JS Herath CB Tehongue J 2009Clin Sci (Lond)2009,117,11:1
5Operating experience with a GaAs photoemission electron source显示文摘Tang F C Lubell M S Rubin K 1986Review of Scientific Instru- ments1986,57,12:1
6Portal pressure responses and angiotensin peptide production in rat hver are determined by relative activity of angiotensin convetting enzyme ( ACE ) and ACE2 显示文摘Herath CB Lubel JS Jia Z 2009Am J Physiol Gastrointest Liver Physiol2009,297,7:1
7Unstiffened steel plate shear wall performance under cyclic loading 显示文摘LUBELL A S PRION H G L VENTURA C E 2000Journal of Structural Engineering2000,126,4:1
8Unstiffened Steel Plate Shear Wall Performance Under Cyclic Loading显示文摘Lubell A S Prion H G L Prion H G L 0,,04:1
9Liver disease and the renin- angiotensin system: recent discoveries and clinical implications显示文摘Lubel JS Herath CB BurreU LM 2008J Gastroenterol Hepatol2008,23,9:1
10Unstiffened Steel Plate Shear Wall Performance Under Cyclic Loading显示文摘 Prion H G L Ventura C V 2000Journal of Structural Engineering2000,126,4:1
11Seeking help from the internetduring adolescence 显示文摘Gould MS Munfakh JL Lubell K 2002J Am Aead ChilAdolese Psychiatry2002,41,10:1
12Enantioselective synthesis of β-amino acids based on BINAP-ruthenium(Ⅱ) catalyzed hydrogenation显示文摘Lubell W D Kitamura M Noyori R 1991Tetrahedron:Asymmwy1991,2,:1
13Unstiffened Steel Plate Shear Wall Performance Under Cyclic Loading 显示文摘Lubell A S Prion G L Ventura C E 2000Journal of Structural Engineering2000,126,4:1
14Current Therapeutics in Primary Sclerosing Cholangitis显示文摘Primary sclerosing cholangitis(PSC)is an orphan,cholestatic liver disease that is characterized by inflammatory biliary strictures with variable progression to end-stage liver disease.Its pathophysiology is poorly understood.Chronic biliary inflammation is likely driven by immune dysregulation,gut dysbiosis,and environmental exposures resulting in gutliver crosstalk and bile acid metabolism disturbances.There is no proven medical therapy that alters disease progression in PSC,with the commonly prescribed ursodeoxycholic acid being shown to improve liver biochemistry at low-moderate doses(15–23 mg/kg/day)but not alter transplant-free survival or liver-related outcomes.Liver transplantation is the only option for patients who develop end-stage liver disease or refractory complications of PSC.Immunosuppressive and antifibrotic agents have not proven to be effective,but there is promise for manipulation of the gut microbiome with fecal microbiota transplantation and antibiotics.Bile acid manipulation via alternate synthetic bile acids such as norursodeoxycholic acid,or interaction at a transcriptional level via nuclear receptor agonists and fibrates have shown potential in phase II trials in PSC with several leading to larger phase III trials.In view of the enhanced malignancy risk,statins,and aspirin show potential for reducing the risk of colorectal cancer and cholangiocarcinoma in PSC patients.For patients who develop clinically relevant strictures with cholestatic symptoms and worsening liver function,balloon dilatation is safer compared with biliary stent insertion with equivalent clinical efficacy.Natassia Tan John Lubel William Kemp Stuart Roberts Ammar Majeed 2023Journal of Clinical and Translational Hepatology2023,11,5:1
15Upregulation of hepatic angiotensin-converting enzyme 2(ACE2)and angiotensin-(1-7)levels in experimental biliarytlbrosis显示文摘Herath CB Warner F J Lubel JS 2007J Hepatol2007,47,3:1
16Amino acid-azetidine chime- ras:Synthesis of enantiopure 3-substituted azetidine-2- carboxylic acids 显示文摘Sajjadi Z Lubell W D 2005The Journal of Peptide Research2005,65,2:1
17Unstiffened steel plate shear wall performance under cyclic loading 显示文摘Lubell A S Prion H G L Ventura C E Rezai M 2000Journal of Structural Engineering ASCE2000,126,4:1
18Unstiffened Steel Plate Shear Wall Performance Under Cyclic Loading显示文摘Lubell A S Prion H G L Ventura C E 2000Journal of Structural Engineering2000,126,4:1
19Unstiffened steel plate shear wall performance under cyclic loading显示文摘Lubell A S Prion H G L Ventura C E 2000Journal of Structural Engineering2000,126,4:1
20Liver fibrosis: a balance ofACEs?显示文摘Warner FJ Lubel JS McCanghan GW 2007Clin Sci (Lond)2007,113,3:1
返回顶部 每页显示:
共7页 首页 上一页 第1页 下一页 末页 /7 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费